Are CK+/CD45+ Double-Positive Circulating Cells of Tumor-origin? Characterization in METAstatic Breast Cancer - Trial NCT06408038
Access comprehensive clinical trial information for NCT06408038 through Pure Global AI's free database. This phase not specified trial is sponsored by Institut Claudius Regaud and is currently Not yet recruiting. The study focuses on Metastatic Breast Cancer. Target enrollment is 60 participants.
This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.
Study Focus
For each patient included, the samples described below will be collected:
Interventional
other
Sponsor & Location
Institut Claudius Regaud
Timeline & Enrollment
N/A
Jun 01, 2024
Jan 01, 2025
Primary Outcome
Rate of patients with proven tumour origin of DP-circulating cells. This is defined as the number of patients with proven tumour origin of DP-circulating cells out of the number of patients with DP-circulating cells.
Summary
A prospective, single-centre, proof-of-concept pilot study in patients with metastatic breast
 cancers (MBC) (whatever the immunohistochemical subtype) treated at the IUCT-O. Eligible
 patients will be selected and informed of this study during a medical consultation for cancer
 that has metastasised, has relapsed or is progressing metastatically, by medical oncologists
 at the Oncopole Claudius Regaud (OCR). Then, with the patient's agreement and before the
 start of anti-tumour treatment, a blood sample will be taken to detect DP-circulating cells.
 A breast cancer tumour sample (non-bone metastasis or, failing that, primary tumour) must be
 available (FFPE archived tumour block).
 
 Each patient will participate in the study for one day.
 
 60 patients will be included in this interventional study.
ICD-10 Classifications
Data Source
ClinicalTrials.gov
NCT06408038
Non-Device Trial